Erratum (Annals of Oncology (2010) 21(S5) (v220–v222), (S0923753419396395), (10.1093/annonc/mdq191));Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages 242-243

  Oberg K ^a   Hellman, P ^a   Kwekkeboom, D ^b   Jelic, S ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; BRONCHUS CARCINOID; BRONCHUS TUMOR; CANCER CLASSIFICATION; CANCER STAGING; CARCINOID; CLINICAL TRIAL; CUSHING SYNDROME; EUROPE; FOLLOW UP; HUMAN; LARGE CELL CARCINOMA; LUNG SMALL CELL CANCER; LUNG TUMOR; NEUROENDOCRINE TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; THYMOMA; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR REGRESSION;

EID: 77954345275     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq690     Document Type: Erratum

References (14)

1. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes: a population-based study in Denmark. Lung Cancer 2002; 37: 127-135.
3. Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000; 114: 100-110.
4. Travis WD. Neuroendocrine lung tumors. Path Case Rev 2006; II: 235-242.
5. Moran CA, Suster S, Coppola D, Wick MR. Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol 2009; 131: 206-221.
6. Travis WD, Giroux DJ, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3: 1213-1223.
7. Travis WD, Rush W, Flieder DB et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22: 934-944.
8. Granberg D, Wilander E, Oberg K, Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 2000; 85: 3425-3430.
9. Jeung MY, Gasser B, Gangi A et al. Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics 2002; 22: 351-365.
10. Daddi N, Ferolla P, Urbani M et al. Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg 2004; 26: 813-817.
11. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl 2): S111-S114.
12. Granberg D, Oberg K. Neuroendocrine tumours. Update Cancer Therapeut 2006; 1: 75-84.
13. Van Essen M, Krenning EP, Kam BL et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009; 5: 382-393.
14. Van Essen M, Krenning EP, Bakker WH et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007; 34: 1219-1227.